NECTIN4 and hematologic disorder: Antigens HER3, Nectin-4, Folatereceptor α, B7H3, CD99, and IGF1R are leading the way with themost ADC drug candidates utilizings these targets for disease treatment.Of disclosed preclinical indications ∼50% are categorized intothe broader solid tumors and hematological malignancy indication withthe other 50% attributed to more specific indications.